What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature
Name:
36288834.pdf
Size:
335.6Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
McNamara, Mairead GBridgewater, J.
Goyal, L.
Jacobs, Timothy
Wagner, A. D.
Goldstein, D.
Shroff, R.
Moehler, M.
Lowery, M.
Bekaii-Saab, T.
Kelley, R. K.
Furuse, J.
Rimassa, L.
Morizane, C.
Lamarca, Angela
Hubner, Richard A
Knox, J.
Valle, Juan W
Affiliation
Department of Medical Oncology, The University of Manchester, Manchester, UKIssue Date
2022
Metadata
Show full item recordAbstract
Objectives: Female physicians in medicine are increasing, but disparities in female authorship exist. The aim of this study was to characterise factors associated with female first (FF) and female senior (SF) authorship in later phase systemic oncological clinical trials in biliary tract cancer (BTC) and identify any changes over time. Setting: Embase/Medline identified trial publications in BTC (2000-2020) were included. χ2 tests and log regression were used (assessed factors associated with FF and SF authorship, including changes over time (STATA V.16)). Primary outcome measure: FF and SF authorship in later phase systemic oncological clinical trials in BTC. Secondary outcome measure: Any changes over time? Results: Of 501 publications, 163 met inclusion criteria. The median percentage of female author representation in publications was 25%; there were no female authors in 13% of publications. Geographic location of the home institution of the first and senior authors was Asia (42%/42%), Europe (29%/29%), USA (24%/22%) and other (4%/6%), respectively. Overall, FF and SF author representation was 20% and 10%, respectively. The median position of the first female author was second in all the publication author lists. The phase of trial, journal-impact factor, industry funding or whether the study met its primary endpoint did not impact FF/SF author representation. More SF authors had home institutions in 'other' geographic locations (40% in 10 trials) (p=0.02) versus Asia (6%), Europe (8%) and USA (14%). There were no significant changes in FF/SF representation over time (p=0.61 and p=0.33 respectively). Conclusions: FF and SF author representation in later phase systemic clinical trial publications in BTC is low and has not changed significantly over time. The underlying reasons for this imbalance need to be better understood and addressed.Citation
McNamara MG, Bridgewater J, Goyal L, Jacobs T, Wagner AD, Goldstein D, et al. What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature. BMJ open. 2022 Oct 26;12(10):e064954. PubMed PMID: 36288834. Pubmed Central PMCID: PMC9615988. Epub 2022/10/27. eng.Journal
BMJ OpenDOI
10.1136/bmjopen-2022-064954PubMed ID
36288834Additional Links
https://dx.doi.org/10.1136/bmjopen-2022-064954Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/bmjopen-2022-064954
Scopus Count
Collections
Related articles
- Prevalence of Female Authors in Case Reports Published in the Medical Literature.
- Authors: Hsiehchen D, Hsieh A, Espinoza M
- Issue date: 2019 May 3
- Trends in Gender of Authors of Patient Blood Management Publications.
- Authors: Forkin KT, Render CM, Staffa SJ, Goobie SM
- Issue date: 2024 Jun 1
- Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
- Authors: Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P
- Issue date: 2022 Feb 1
- Authorship Equity and Gender Representation in Global Oncology Publications.
- Authors: Hornstein P, Tuyishime H, Mutebi M, Lasebikan N, Rubagumya F, Fadelu T
- Issue date: 2022 Jan
- A Decade in Review: Trends in Female Authorship in Peer-Reviewed Toxicology Journals.
- Authors: Love JS, Loo GT, Murphy L, Temple C, Spyres MB, Manini AF, O'Connor AD
- Issue date: 2024 Jan